IGN-311. Igeneon.

Article Details

Citation
Copy to clipboard

Kristeleit H

IGN-311. Igeneon.

Curr Opin Investig Drugs. 2005 Dec;6(12):1272-9.

PubMed ID
16370394 [ View in PubMed
]
Abstract

Igeneon, under license from Protein Design Labs, is developing IGN-311, an intravenous humanized monoclonal antibody against the Lewis Y carbohydrate antigen, as a potential agent for the passive immunotherapy of cancer, particularly epithelial tumors affecting breast, colon, gastric and pancreatic tissues. A phase I/II trial of IGN-311 was initiated in July 2005.

DrugBank Data that Cites this Article

Drugs